25 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
Children'S Hospital Medical Center
Combination therapies using immuno-dash inhibitors and PGE2 antagonists
Tufts College
Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
Ogeda
Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
Oryzon Genomics
Substituted 2-aminopyridine protein kinase inhibitor
Chia Tai Tianqing Pharmaceutical Group
Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity.
Roche Products
Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.
Merck Sharp and Dohme Research Laboratories
Potent, orally bioavailable HIV-1 protease inhibitors containing noncoded D-amino acids
Eli Lilly
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Johns Hopkins University
An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Academy of Sciences of The Czech Republic
Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.
University of Queensland
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
National Cancer Institute-Bethesda
Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.
Upjohn
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Upjohn
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
Merck Research Laboratories
L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.
Merck Research Laboratories
Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.
Uppsala University
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
The Johns Hopkins University